CRB Health Tech Research
Investment Thesis
CRB Health Tech (formerly CRB Inverbío / Cross Road Biotech) is an independent Madrid- and Barcelona-based private capital management firm founded in 2008 by Enrique Castellón, specialized exclusively in Health Technologies: biotechnology, medical devices, and digital health. The firm's core belief is that differential technology born from Spain's scientific and clinical research environment can be professionalized and scaled into internationally competitive companies. Over three fund generations the firm has moved from early biotech and medtech investing (Fund I, Fund II) into a dedicated digital health strategy (CRB Digital Health Tech III), reflecting the founders' view that digital health has evolved "from hype into infrastructure." The firm positions itself as a hands-on partner, embedding operational, industrial, and technological expertise into portfolio companies rather than acting as a passive check-writer.
Stage Focus
CRB Digital Health III, the firm's current active vehicle, targets Seed and Series A companies that have already passed clinical or regulatory validation and are ready to scale commercially. This is a deliberate shift from the earlier, more R&D-heavy biotech funds (Fund I, Fund II) toward commercially de-risked digital health businesses with faster paths to revenue.
Check Size
Initial tickets range from €500K to €1.5M-€2M, with reserved follow-on capital allowing total exposure per company of up to €4-5M. The firm expects to build a portfolio of approximately 25 companies in Fund III through this ticket structure.
Lead Tendency
Public materials do not explicitly describe CRB as a lead-only or follow-only investor; the firm emphasizes being a strategic, hands-on partner and has taken significant, board-level positions historically (e.g., Health in Code from 2013), suggesting a lead or co-lead posture on core positions, but this is not confirmed for every Fund III deal.
Recent Activity
CRB Digital Health III held its first close in mid-2024 with €20M, anchored by Sanitas (Bupa) as a reference investor, followed by Roca Group Ventures joining in July 2024. The fund reached a final close of €50M in 2026, roughly 1.7x its original ~€30M target, with a broad investor base spanning insurers (Sanitas/Bupa, Occident), pharma/industrial players (Cantabria Labs, Aldo-Unión, GP Pharm, Reig Jofré), financial investors (CBNK), and public institutions (Spanish government's SETT, CDTI, Institut Català de Finances, Barcelona City Council). As of the final close, the fund had approved roughly ten investments across Spain, Germany, France, Italy, the Netherlands, and the UK. Separately, CRB Bio II (the firm's life-sciences vehicle) fully exited its long-held position in Health in Code in February 2026, a genomics diagnostics company CRB backed from 2013 through a later Alantra-led buy-and-build, realizing roughly a 3x return multiple on the continuation transaction.
Portfolio Highlights
Digital Health III portfolio includes Thryve (wearable health data SaaS), Carol (virtual primary care for employers), Livo (healthcare staffing SaaS), Prosoma (digital psycho-oncology support), Toothfairy (teledentistry), Zoundream (AI analysis of infant cries), Circle Health (personalized care navigation), Waiv (AI-based pathology diagnostics), and Trak (computer-vision-based physio rehab). Earlier funds backed Health in Code (genomics, exited 2026 at ~3x), Oncovision (PET/molecular imaging), AMADIX (blood-based cancer detection), NUUBO (wearable cardiac textiles), Mecwins (nanomechanical biosensors), Biocross (Alzheimer's biomarkers), TCD Pharma, Green Molecular, OWL Metabolomics, nLife Therapeutics, Raman Health Technologies, Iden Biotechnology, and Aglaris Cell.
Team
- Enrique Castellón, Partner (founder, 2008)
- Ángel Santos, Partner
- Joaquín Velasco, Partner (President)
- Manuel Castellón, Partner
- Alejo Costa Ribalta, Partner / General Partner (leads Digital Health III alongside Ignasi Heras)
- Ignasi Heras, Partner / General Partner
- Tim Juergens, Partner
- Antonio Serrano, Strategic Advisor
- María Jaraiz, Partner
- Isabel Santamaría, Head of Financial & Admin
- Beatriz Plaza, Investment Associate
- Brigida Escudero, Administrative Support
- Samantha López-Mochales, Investment Analyst
Decision Process
The firm operates as a multi-partner team (13 listed team members including partners, GPs, and investment staff) rather than a solo GP, consistent with an investment-committee or partnership-style decision process across a founding executive team assembled since 2008.
Founder Preferences
CRB favors technical/scientific founders building on validated clinical or regulatory groundwork rather than pre-validation science projects. For Fund III, the firm explicitly seeks founders in AI-applied diagnostics, mental health, hospital digitalization, remote monitoring, and healthcare efficiency tooling who are ready to commercialize and scale internationally.
Geographic Focus
Headquartered in Madrid, with a second office in Barcelona, giving reach across Spain and wider European innovation hubs. Fund III's approved investments span Spain, Germany, France, Italy, the Netherlands, and the UK, with roughly half the portfolio expected to have a Spanish presence.